SCHEMBL18409481

SCHEMBL18409481

Oc1ccccc1N1CCN(Cc2nc(-c3ccccc3)c(-c3ccccc3)o2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 2/20 0.49
NR4A2 P43354 9/20 0.47
NR4A1 P22736 2/20 0.47
NR4A3 Q92570 2/20 0.47
ALDH1A1 P00352 4/20 0.47
GAA P10253 3/20 0.47
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
RXRA P19793 4/20 0.45
RXRB P28702 3/20 0.45
DRD2 P14416 2/20 0.45
DRD3 P35462 2/20 0.45
RXRG P48443 2/20 0.45
KDM4E B2RXH2 2/20 0.45
HPGD P15428 2/20 0.45
ABCC4 O15439 1/20 0.45
C5 P01031 1/20 0.45
LMNA P02545 1/20 0.45
CHRM2 P08172 1/20 0.45
CYP3A4 P08684 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18409299 0.84 MAPT (0.60) DRD4NR4A2NR4A1NR4A3ALDH1A1
SCHEMBL18409485 0.83 GAA (0.56) DRD4NR4A2NR4A1NR4A3ALDH1A1
SCHEMBL18409735 0.81 KCNH2 (0.58) DRD4NR4A2NR4A1NR4A3ALDH1A1
SCHEMBL11717178 0.81 HRH3 (0.54) NR4A2NR4A1NR4A3ALDH1A1RXRA
SCHEMBL18409489 0.81 DRD2 (0.57) DRD4NR4A2NR4A1NR4A3ALDH1A1
SCHEMBL11716952 0.80 NR4A2 (0.54) NR4A2NR4A1NR4A3RXRARXRB
SCHEMBL18409627 0.79 MAPT (0.54) DRD4ALDH1A1DRD2DRD3KDM4E
SCHEMBL18409494 0.79 MAPT (0.51) DRD4NR4A2NR4A1NR4A3ALDH1A1
Hydrochloric Acid SCHEMBL11718299 0.78 RAB9A (0.58) NR4A2NR4A1NR4A3ALDH1A1RXRA
SCHEMBL11714345 0.78 NR4A2 (0.51) NR4A2NR4A1NR4A3ALDH1A1RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10844051-B2 Substituted oxazoles for the treatment of cancer THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY 2020-11-24 US disclosed
US-20200339554-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2020-10-29 US disclosed
US-20180208586-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2018-07-26 US disclosed
WO-2017011920-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2017-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180208586-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS VHL, TP53, CD44 DRD4 4787/4885NR4A2 1603/4885NR4A1 2245/4885
US-10844051-B2 Substituted oxazoles for the treatment of cancer OXA1L, PDCD1, MCL1 DRD4 4586/4885NR4A2 336/4885NR4A1 708/4885
US-20200339554-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS KRAS, NRAS, VHL DRD4 4249/4885NR4A2 2489/4885NR4A1 1760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.